BeOne Medicines AG (ONC) fair value analysis
Nasdaq · Updated 2026-09-07
BeOne Medicines AG is a biopharmaceutical company that focuses on the development of therapies for oncology and other serious diseases. The company is headquartered in Switzerland and operates as a publicly traded entity on the Nasdaq stock exchange.
Valuation status
Awaiting full valuationONC does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $313.77
- Sector
- Healthcare
- 12-month range
- $279.68–$345.00
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Low
- RSI zone
- Neutral
- 50/200-day trend
- Mixed
- 52-week position
- The upper-middle quarter of its range
What our data shows for ONC
- Our model validated 2 trailing price-to-earnings windows for ONC, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $279.68–$345.00.
- The 14-day relative strength index sits at a neutral 59.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ONC
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
What people are saying
Follow the ONC conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is ONC stock undervalued?
ONC does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is ONC's TickrTrends verdict?
ONC is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is ONC overbought or oversold?
ONC's 14-day RSI is in neutral territory - neither overbought nor oversold.